Company Overview
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment malignant pleural mesothelioma, non-small cell lung, gastric/gastro-esophageal, head and neck squamous cell carcinoma, pancreatic, renal, ovarian, prostate, breast, cervical, colorectal, endometrial, and bladder cancers; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -74.7%.
- 5-Year Trend Long-term compounding — revenue CAGR -28.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -28.81% |
| 1 Year: | -74.67% |
Stock Price Performance
| 1 Year: | -94.53% |
| 6 Months: | -72.09% |
| 3 Months: | -61.55% |
| 1 Month: | -55.02% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)28.59 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -28.8% CAGR over 5 years.
- Trading 95.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | APVO Aptevo Therapeutics Inc. PHARMA | 1.88 | 0.00 | $3.40M | 0.00% | -124.44% | - | -28.81% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 3.53M | 6.17M | 4.07M | 6.83M | 5.82M | 7.02M | 7.36M | 9.01M | - | 473.00K | 1.46M | 2.42M | 3.11M | 3.10M | 3.11M | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -11.10M | -18.31M | -13.19M | -18.50M | -12.98M | -12.85M | -90.53M | -14.55M | -12.13M | -14.65M | -10.35M | -13.50M | -12.44M | -12.13M | -11.44M | -12.90M | -11.46M | -7.62M | -6.81M | -6.25M | -6.89M | -5.72M | -4.75M | -5.61M | -7.56M | -7.78M | -7.76M | -8.18M | -6.56M | -6.98M | -6.02M | -5.21M | -6.48M | -6.23M | -7.61M | -6.84M |
| Net Income | -11.02M | -17.72M | -12.68M | -17.90M | -12.89M | -12.84M | -71.74M | -14.95M | -9.95M | -11.19M | 37.87M | -13.85M | -13.14M | -12.56M | -12.02M | -13.33M | -6.92M | 2.90M | -6.80M | -6.79M | -7.26M | -7.93M | -7.00M | -7.70M | 28.01M | -7.64M | 2.77M | -7.95M | -6.33M | -6.83M | -5.88M | -5.10M | -6.41M | -6.20M | -7.55M | -6.70M |
| Diluted EPS | - | - | - | - | - | - | -3.55 | - | - | - | 1.75 | - | - | -0.56 | - | - | - | - | - | - | - | -1.75 | -1.43 | -1.55 | 5.58 | -1.50 | 17.38 | -53.95 | -22.16 | -368.21 | -1,236.96 | -357.86 | -1,581.81 | -8.40 | -2.23 | -6.41 |
| R&D Expense | - | - | 7.71M | - | 8.10M | 7.64M | 7.08M | - | 5.87M | 6.79M | 7.17M | 8.20M | 9.71M | 8.57M | 6.63M | 6.12M | 7.60M | 4.01M | 4.44M | 4.49M | 5.36M | 4.72M | 4.37M | 4.87M | 3.87M | 4.48M | 4.17M | 5.46M | 3.89M | 3.75M | 3.64M | 3.10M | 3.63M | 3.33M | 4.04M | 3.92M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 33.60M | 9.98M | 14.66M | 23.07M | 32.42M | 4.31M | 12.29M | 3.11M | - | - | - |
| Operating Income | -61.10M | -138.77M | -53.95M | -51.66M | -40.96M | -27.49M | -21.40M | -28.64M | -28.88M | -24.60M | -26.31M |
| Net Income | -59.32M | -112.42M | 6.97M | -53.69M | -40.45M | -17.75M | -28.46M | 8.03M | -17.41M | -24.13M | -25.97M |
| Diluted EPS | - | - | - | - | - | - | -6.07 | 1.57 | -2,316.83 | -31,460.23 | -87.27 |
| R&D Expense | 34.73M | 29.12M | 29.02M | 35.38M | 24.76M | 17.85M | 18.99M | 17.88M | 17.11M | 14.38M | 14.54M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Mar 2016 | Jun 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 127.77M | 127.92M | 133.47M | 91.86M | 117.01M | 67.49M | 53.41M | 53.55M | 56.60M | 34.22M | 24.84M | 15.59M | 27.19M |
| Total Equity | 94.61M | 88.62M | 89.86M | 97.20M | 50.57M | 82.03M | 30.41M | 11.84M | 16.59M | 1.22M | 17.97M | 12.22M | 4.75M | 17.38M |
| Cash & Equivalents | 3.59M | 4.64M | - | - | 9.68M | 7.09M | 30.64M | 12.45M | 39.98M | 45.04M | 22.64M | 16.90M | 8.71M | 21.62M |
| Long Term Debt | - | - | - | - | 18.38M | 15.73M | 19.28M | - | 28.22M | 3.71M | 1.46M | 0 | - | - |
| Total Liabilities | - | 39.15M | 38.05M | 36.27M | 41.29M | 34.97M | 37.09M | 41.57M | 36.95M | 55.38M | 16.24M | 12.62M | 10.84M | 9.81M |
| Current Liabilities | - | 19.94M | - | - | 19.54M | 18.51M | 17.61M | 38.24M | 14.54M | 34.76M | 8.71M | 7.22M | 6.21M | 6.05M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | -41.57M | -51.42M | -42.38M | -29.32M | -21.68M | -21.02M | -11.73M | -23.79M | -25.59M |
| Investing Cash Flow | - | - | 29.46M | 72.80M | 4.10M | 28.03M | -713.00K | -29.00K | 0 | 0 | 0 |
| Financing Cash Flow | - | - | 19.53M | -787.00K | 20.15M | 23.87M | 26.16M | -2.62M | 6.00M | 15.60M | 38.50M |
| Capital Expenditure | -1.53M | -2.51M | -1.40M | -976.00K | -153.00K | -88.00K | -713.00K | -29.00K | - | - | - |
| Free Cash Flow | - | - | -42.98M | -52.40M | -42.54M | -29.41M | -22.39M | -21.05M | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -181.8% | -1,389.8% | -368.1% | -224.0% | -126.3% | -638.1% | -174.1% | -919.7% | - | - | - |
| Net Margin % | -176.5% | -1,125.8% | 47.6% | -232.8% | -124.7% | -411.9% | -231.5% | 257.8% | - | - | - |
| ROE % | -66.9% | -222.3% | 8.5% | -176.6% | -341.6% | -107.0% | -2,340.2% | 44.7% | -142.5% | -507.5% | -149.4% |
| ROCE % | -56.7% | -191.9% | -54.8% | -103.6% | -270.0% | -70.5% | -98.0% | -112.3% | -163.9% | -262.2% | -124.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | GSA Capital Partners LLP | 1.19% | 21.54K | $39.63K |
| 2 | Vanguard Capital Management LLC | 0.70% | 12.71K | $23.39K |
| 3 | Geode Capital Management, LLC | 0.60% | 10.82K | $19.91K |
| 4 | Vanguard Fiduciary Trust Co | 0.23% | 4.14K | $7.62K |
| 5 | UBS Group AG | 0.04% | 730 | $1.34K |
| 6 | Osaic Holdings Inc. | 0.02% | 360 | $662 |
| 7 | SBI Securities Co., Ltd. | 0.01% | 109 | $200 |
| 8 | CWM, LLC | - | 5 | $9 |
| 9 | Danske Bank A/s | - | 1 | $1 |
| 10 | Barclays Plc | - | 31 | $57 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for APVO
Aptevo Therapeutics Inc. SEC Filing (Sep 3, 2026) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxOeHE1RTZhVldLTjVfZnZJVWdGV0g5cHNqSFZBb0MwSVB1MUlWZThfaHBZYzFKeUVFNk94MHV0UG1zUjZ4Q21LZ1pEUWdxUjh4b1I1UUxKR1VzQ2R3ZElkTmJweFFQcS1kQzk2bWlZZDFvdlBSb1psWWNrQ0I4d3lrUzk5ajY5LS1oX3ZNWE…
APVO Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBSSGNiVkNvdktRY3hWU3llWXRCYXgyT1U0WXA4OEFrcUVQNFRRVENmcnpGOGg0RUJ3U1M0dDZuMm0zSHhaUEc0VVRJZjlkWmwzM3lVY2MzLTF6Y2xKdTR1YjhkYVE0QzhlN2RjQmdXaS1kd2hHZ3FoUEJn?oc=5" target="_blank">APV…
Aptevo Therapeutics (APVO) Shares Fall Despite Roth Capital Opti - gurufocus.com
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxPemVQOHJyNlM2WEwzSmdTX19uX2ZabERVU25fQ1FRaDE5UVRUeHJrUDVod25xcTQ1UklxZjZ6alU4V05nYnB3OWhzd0VYRV9MdEVvN1JUYTlpUTRmRnczZHBtM05DaWNuNjFjZ1hrZ2tuTVpzMnhvZ0hBekdUVGVOUEx0ZHF6UFViMWVIVl…
APVO Stock - Immuno-Oncology Company To Watch Petersburg (cK2qyfq7CG) - Mshale
<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTE1hdXJENFZqTk1PRjF2MEY1ZU0xLWR2VnF5Ykh6YmswS1pnNjdmNFJlZ0h3M1Z0V1JXX1VmR242N1pkcnJvekZTOHpuY0ZXclhJT09qMzZ4QzJWN1k?oc=5" target="_blank">APVO Stock - Immuno-Oncology Company To Watc…
Aptevo APVO Reports Q2 2026 Update With $9.8 Million Cash - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPeGFjZTRSR2NXS25nMm9fN0JuYWEzV0tIeERMdmwzRVlobHdOWW5UR3ZXdkRHTlp1OVFPZGFrVG9sTDRqczdEREh6eG1xZ2R4Q3V3eTh0LUJFamUtTlVIemlEUnZiTlltY2pFVkx1OFZURHlaWGpRT0M0WGhHcDYyN05Gd2JiR3ZEd1FQND…
Aptevo Therapeutics (APVO) Upgraded to Buy: Here's Why - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOY1prZGpabUs5ck5vZXB0blhDQVNZWmtucEdlZF9zQWRJSkxGb3d6R2kzemZXVG9leUtQeEpTVS1yQU9waTgtbmNLSnRnd21xU3NhWjhVeVlKOUlSLUI2eHhHRHgyLTNBdUVneHdacXo3RzNjNm53elV1TWtURElZZGJfVHpYNjNGQVVJeT…
APVO — Frequently Asked Questions
What is the current share price of Aptevo Therapeutics Inc. (APVO)?
As of 2026-09-19 21:16 PDT, Aptevo Therapeutics Inc. (APVO) trades at $1.88 on NasdaqCM. Its 52-week range is $1.71 to $37.26.
What is the market capitalisation of APVO?
Aptevo Therapeutics Inc. (APVO) has a market capitalisation of $3.40M on NasdaqCM.
Is APVO a good stock to buy?
This page provides a data-driven analysis of Aptevo Therapeutics Inc. (APVO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.